Glenmark's Ichnos Sciences Secures $320 Million Licensing Deal

12 Oct 2023 , 03:32 PM

Glenmark Pharmaceuticals’ subsidiary, Ichnos Sciences, signs a global licensing deal with Astria Therapeutics for its OX40 antagonist monoclonal antibody portfolio. The licensing agreement encompasses use in inflammatory and immune diseases, securing USD 320 million for Ichnos.

Astria will take on all costs and responsibilities for the global development and commercialization of the therapeutic program. Ichnos to focus on advancing its oncology pipeline, utilizing the proceeds to fuel further research and development.

Astria sees potential to deliver a best-in-class treatment for atopic dermatitis patients using the OX40 antagonist and YTE half-life extension technology.

For feedback and suggestions, write to us at [e-mail]